Cargando…
Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
BACKGROUND: The main pathophysiological basis of coronavirus disease 2019 (COVID-19) causing respiratory failure is a cytokine storm and interleukin-6 (IL-6) is an important component of the COVID-19 cytokine storm. As a specific antagonist of IL-6, tocilizumab may block the cytokine storm of COVID-...
Autores principales: | Zeng, Jia, Xie, Ming-Hui, Yang, Jing, Chao, Sheng-Wu, Xu, Er-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479568/ https://www.ncbi.nlm.nih.gov/pubmed/32953852 http://dx.doi.org/10.12998/wjcc.v8.i17.3763 |
Ejemplares similares
-
Clinical features and risk factors of severely and critically ill patients with COVID-19
por: Chu, Xin, et al.
Publicado: (2022) -
Efficacy of combination of localized closure, ethacridine lactate dressing, and phototherapy in treatment of severe extravasation injuries: A case series
por: Lu, Yan-Xu, et al.
Publicado: (2021) -
Clinical study on the surgical treatment of atypical Lisfranc joint complex injury
por: Li, Xu, et al.
Publicado: (2020) -
Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases
por: Zhu, Hong-Ming, et al.
Publicado: (2020) -
Efficacy and safety of endoscopic retrograde cholangiopancreatography in recurrent pancreatitis of pediatric asparaginase-associated pancreatitis
por: Yang, Kai-Hua, et al.
Publicado: (2023)